This study investigates the therapeutic potential of thymoquinone (TQ), the principal active compound of Nigella sativa, in collagen II-induced rheumatoid arthritis (RA) in male rats using both in silico and in vivo approaches to explore its anti-inflammatory and antioxidant properties. The work was conducted in two phases. In the in silico phase, molecular docking was employed to predict the binding interactions between TQ and key RA targets, including pro-inflammatory cytokines (IL-1β, IL-6, NF-κB, TNF-α) and antioxidant enzymes (catalase and superoxide dismutase, SOD). In the in vivo phase, RA was induced by intradermal injection of type II collagen emulsified with complete Freund's adjuvant. After arthritis confirmation, rats were randomly divided into groups and treated orally with different doses of TQ for 40 consecutive days. Paw thickness was measured regularly to monitor inflammation. At the end of the experiment, blood and tissue samples (liver, spleen, and joint synovium) were collected to evaluate oxidative stress biomarkers, including catalase (CAT), SOD, glutathione (GSH), and malondialdehyde (MDA). Radiographic imaging and histological analyses were performed to assess joint damage, while liver and kidney function tests evaluated treatment safety. Molecular docking analyses revealed strong binding affinities between TQ and inflammatory as well as oxidative stress-related macromolecules, suggesting that TQ can modulate key pathways involved in RA pathogenesis. In vivo, TQ treatment significantly reduced paw swelling, improved joint histopathology, and restored antioxidant enzyme activities. Furthermore, TQ normalized GSH and MDA levels without inducing hepatotoxicity or nephrotoxicity. Radiographic and histological evaluations confirmed reduced joint destruction, preservation of cartilage and bone integrity, and decreased synovial inflammation. Collectively, these findings indicate that TQ exerts potent anti-inflammatory and antioxidant effects with a favorable safety profile, supporting its potential as a promising therapeutic candidate for rheumatoid arthritis management.
扫码关注我们
求助内容:
应助结果提醒方式:
